Synonyms: TPX-0131 | TPX0131
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN zotizalkib, It maps via PubChem to the lead anaplastic lymphoma kinase (ALK) inhibitor TPX-0131 [1]. TPX-0131 is orally bioavailable, and crosses the blood-brain barrier in a preclinical model.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Turning Point Therapeutics have advanced TPX-0131 to clinical evaluation to determine efficacy against advanced/metastatic solid tumours with ALK inhibitor resistance (induced by repotrectinib-resistant mutations, for example) [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | Phase 1/Phase 2 Interventional | Turning Point Therapeutics, Inc. |